Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04064840
PHASE3

GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET

Sponsor: The University of Hong Kong

View on ClinicalTrials.gov

Summary

The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.

Official title: Gonadotrophin Releasing Hormone Agonist for Dual Trigger in in Vitro Fertilization and for Luteal Phase Support in Frozen-thawed Embryo Transfer

Key Details

Gender

FEMALE

Age Range

18 Years - 42 Years

Study Type

INTERVENTIONAL

Enrollment

784

Start Date

2019-09-01

Completion Date

2025-03-30

Last Updated

2024-12-06

Healthy Volunteers

No

Conditions

Interventions

DRUG

IVF: Decapeptyl and hCG

When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.

DRUG

FET: Decapeptyl

On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.

DRUG

IVF: hCG and normal saline

When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.

DRUG

FET: Normal Saline

On the day of FET, normal saline will be injected subcutaneously.

Locations (1)

Department of Obstetrics and Gynaecology

Hong Kong, Hong Kong, China